Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586774 | 0.80 | CYP19A1 (0.41) | — | |
| SCHEMBL3823645 | 0.80 | HTR2A (0.51) | GCKRIPK1 | |
| SCHEMBL8536248 | 0.77 | GCK (0.44) | GCKDAORIPK1 | |
| SCHEMBL18590955 | 0.76 | GCK (0.46) | GCKDAORIPK1 | |
| SCHEMBL7396037 | 0.72 | HRH1 (0.52) | — | |
| SCHEMBL2037835 | 0.72 | GCK (0.71) | GCK | |
| SCHEMBL1960655 | 0.71 | GCK (0.52) | GCK | |
| SCHEMBL5397116 | 0.70 | SLC6A3 (0.36) | — | |
| SCHEMBL1962013 | 0.68 | GCK (0.75) | GCK | |
| SCHEMBL8135643 | 0.68 | RIPK1 (0.47) | GCKDAORIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | GCK 1402/4885DAO 1188/4885RIPK1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.